2022 Fiscal Year Final Research Report
Elucidation of the cancer growth mechanism mediated by the amplified gene SOX2 and the AKT pathway in lung squamous cell carcinoma and its application to treatment
| Project/Area Number |
21K16528
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 55040:Respiratory surgery-related
|
|---|
| Research Institution | Kanazawa Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2021-04-01 – 2023-03-31
|
| Keywords | 肺癌 / 扁平上皮癌 / SOX2 / PI3K/AKT/ｍTOR経路 / 分子標的治療薬 |
|---|
| Outline of Final Research Achievements |
Clarification of the oncological and molecular biological characteristics of SOX2-positive squamous cell carcinoma is extremely important for the development of new treatments for lung squamous cell carcinoma. From this point of view, it is extremely important to clarify the molecular networks affected and regulated by SOX2, and the interdependence between SOX2 and the PI3K/AKT/mTOR pathway has attracted attention. In this study, we elucidated the action mechanism of SOX2 on downstream effectors via the PI3K/AKT/mTOR pathway, and conducted a basic investigation of molecular target therapy for lung squamous cell carcinoma.
|
| Free Research Field |
胸部外科
|
| Academic Significance and Societal Importance of the Research Achievements |
癌の分子生物学的進歩により, 癌の発生や進展機構が急速に解明されつつある. とりわけ, ゲノム解析をはじめとする網羅的分子解析技術の進歩は目覚ましく, これらの機構解明に留まらず, 新しい治療標的分子の発見から癌分子標的治療薬の開発が加速している. 肺癌でも, 特に腺癌でEGFR遺伝子変異やALK融合遺伝子に対する分子標的治療薬の進歩が顕著である. 一方で扁平上皮癌においては, 現在まで治療標的となるドライバー遺伝子変異は確認されておらず, 実用化された分子標的治療薬はない. 癌遺伝子の活性化を導く遺伝子増幅の標的を同定し,癌発生の分子機構の解明に寄与する.
|
